SCHEMBL4193797

SCHEMBL4193797

N#Cc1cccc(S(=O)(=O)Nc2cccc(C3CNC3)c2)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PGR P06401 1/20 0.51
KDM1A O60341 1/20 0.51
MAOA P21397 1/20 0.51
BRD4 O60885 1/20 0.50
DRD2 P14416 1/20 0.49
DRD3 P35462 1/20 0.49
BRD1 O95696 1/20 0.47
BRPF1 P55201 1/20 0.47
HTR6 P50406 1/20 0.46
HSPD1 P10809 1/20 0.46
PTPN2 P17706 1/20 0.46
PTPN1 P18031 1/20 0.46
PTPN5 P54829 1/20 0.46
HSPE1 P61604 1/20 0.46
SGK1 O00141 1/20 0.45
HSD17B1 P14061 2/20 0.44
HSD17B2 P37059 2/20 0.44
GLO1 Q04760 1/20 0.44
SLC40A1 Q9NP59 1/20 0.44
TRIM24 O15164 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4186732 0.83 KMT2A (0.53) PGRHSPD1PTPN2PTPN1PTPN5
SCHEMBL4204669 0.81 LMNA (0.54) MAPT
SCHEMBL4204846 0.81 PGR (0.59) PGRBRD4MAPT
SCHEMBL4198524 0.79 GAA (0.55) PGRBRD4
SCHEMBL4204724 0.79 TSHR (0.55) PGRHTR6HSPD1PTPN2PTPN1
SCHEMBL19334523 0.78 PGR (0.77) PGRBRD4BRD1BRPF1HTR6
SCHEMBL4193915 0.78 CYP19A1 (0.49) PGRHTR6MAPTACLY
SCHEMBL14869628 0.77 DRD2 (0.76) DRD2DRD3
SCHEMBL4196434 0.76 BRAF (0.53) PGRDRD2DRD3SLC40A1SLC22A12
SCHEMBL4200550 0.76 HDAC3 (0.46) PGRBRD4TRIM24

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8642642-B2 Heterocyclic arylsulphones suitable for treating disorders that respond to modulation of the serotonin 5HT6 receptor ABBOTT LABORATORIES (US) 2014-02-04 US disclosed
US-20090306175-A1 HETEROCYCLIC ARYLSULPHONES SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5HT6 RECEPTOR ABBOTT GMBH & CO. KG (DE) 2009-12-10 US disclosed
EP-2029528-A1 HETEROCYCLIC ARYLSULPHONES SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5HT6 RECEPTOR Abbott GmbH & Co. KG (DE) 2009-03-04 EP disclosed
WO-2007118899-A1 HETEROCYCLIC ARYLSULPHONES SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5HT6 RECEPTOR ABBOTT GMBH & CO. KG (DE) 2007-10-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090306175-A1 HETEROCYCLIC ARYLSULPHONES SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5HT6 RECEPTOR HTR6, HTR1A, HTR5A PGR 492/4885KDM1A 2179/4885MAOA 71/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.